에 대한 최신 뉴스 Geron (NASDAQ:GERN) 주식

Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Geron Corp

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AKRO

AMGN

EWTX

GERN

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Needham analyst Gil Blum reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and maintains $5 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Geron, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) from Neutral to Neutral.

HC Wainwright & Co. Reiterates Neutral on Geronto Neutral

Geron Corporation Announces That The European Commission Has Granted Marketing Authorization For Rytelo As A Monotherapy For The Treatment Of Adult Patients With Transfusion-Dependent Anemia

Management

Geron Corporation Announces That John "Chip" A. Scarlett, M.d., President, Chief Executive Officer And Chairman, Will Depart The Company Effective March 31, 2025

Scotiabank analyst Greg Harrison maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Sector Outperform and lowers the price target from $6 to $4.

Scotiabank Maintains Sector Outperform on Geron, Lowers Price Target to $4

Stifel analyst Stephen Willey maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and lowers the price target from $8 to $4.

Stifel Maintains Buy on Geron, Lowers Price Target to $4

Barclays analyst Peter Lawson maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Overweight and lowers the price target from $9 to $4.

Barclays Maintains Overweight on Geron, Lowers Price Target to $4

Needham analyst Gil Blum maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and lowers the price target from $7 to $5.

Needham Maintains Buy on Geron, Lowers Price Target to $5

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday.
The Dow traded down 0.32% to 43,482.16 while the NASDAQ gained 0.07% to 19,038.99. The S&amp;P 500 also fell, dropping, 0.01% to 5,954.69.
Check This Out: <a href="https://www.benzinga.com/25/02/43952829/top-3-materials-stocks-that-may-keep-you-up-at-night-in-february">Top 3 Materials Stocks That May Keep You Up At Night In February</a>
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Wednesday.
In trading on Wednesday, consumer staples shares fell by 1.5%.
Top Headline
TJX Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) posted better-than-expected fourth-quarter FY25 earnings results.
The company's fourth-quarter FY25 sales remained flat year-on-year to $16.4 billion, beating the analyst consensus estimate of $16.20 billion.
Overall comp store sales increased 5%, well above the Company's plan, and were driven by an increase in customer transactions. Adjusted EPS of $1.23 beat the consensus estimate of $1.16.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares shot up 116% to $2.54 after the company announced its non-hallucinogenic psychedelic compounds showed promise for treating addiction and ADHD.</li>
<li>Shares of Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>)got a boost, surging 59% to $3.72 after the company announced that its Mullen ONE and Mullen THREE vehicles have been added to National Auto Fleet Group&#8217;s Sourcewell contract for public sector government purchasing.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares were also up, gaining 80% to $6.80 after the company reported fourth-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) shares dropped 40% to $10.67 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) were down 17% to $311.57 with two new short reports adding to the targets against the high-rising stock.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) was down, falling 31% to $1.6250 after the company posted quarterly results.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $68.79 while gold traded up 0.4% at $2,930.50.
Silver traded up 1.1% to $32.165 on Wednesday, while copper rose 1.2% to $4.5795.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.99%, Germany's DAX 40 gained 1.71% and France's CAC 40 climbed 1.15%. Spain's IBEX 35 Index rose 1.64%, while London's FTSE 100 rose 0.72%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.25%, China's Shanghai Composite Index gaining 1.02% and Hong Kong's Hang Seng Index surging 3.27%.
Economics
<ul>
<li>U.S. mortgage applications declined by 1.2% from the previous week during the week ending Feb. 21</li>
<li>U.S. crude oil inventories declined by 2.332 million barrels in the week ended Feb. 21, compared to market estimates of a 2.54 million gain, the EIA said.</li>
<li>Sales of new single-family homes in the U.S. dipped 10.5% to an annualized rate of 657,000 in January.</li>
<li>Building permits declined by 0.6% to an annualized rate of 1.473 million in January.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ENVB

FLYW

MULN

PRCH

Dow Dips Over 100 Points; TJX Earnings Top Views

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday.
The Dow traded down 0.06% to 43,594.06 while the NASDAQ gained 0.87% to 19,192.72. The S&amp;P 500 also rose, gaining, 0.46% to 5,983.30.
Check This Out: <a href="https://www.benzinga.com/25/02/43952829/top-3-materials-stocks-that-may-keep-you-up-at-night-in-february">Top 3 Materials Stocks That May Keep You Up At Night In February</a>
Leading and Lagging Sectors Information technology shares jumped by 1.4% on Wednesday.
In trading on Wednesday, consumer staples shares fell by 1.6%.
Top Headline
Lowe's Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) reported better-than-expected fourth-quarter earnings.
The company reported adjusted earnings per share of $1.93 above the street view of $1.84. Quarterly sales were $18.553 billion, a slight decline of 0.3% year over year, but they outpaced the analyst consensus estimate of $18.292 billion.
Lowe's said it sees 2025 EPS of $12.15–$12.40, below the $12.51 consensus estimate. Total sales are projected at $83.5 billion – $84.5 billion, compared to the $84.56 billion consensus.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares shot up 108% to $2.4540 after the company announced its non-hallucinogenic psychedelic compounds showed promise for treating addiction and ADHD.</li>
<li>Shares of Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>)got a boost, surging 72% to $4.0685 after the company announced that its Mullen ONE and Mullen THREE vehicles have been added to National Auto Fleet Group&#8217;s Sourcewell contract for public sector government purchasing.</li>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares were also up, gaining 65% to $6.25 after the company reported fourth-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) shares dropped 41% to $10.48 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Shares of Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) were down 34% to $0.3540. Venus Concept recently announced several senior management changes.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) was down, falling 31% to $1.64 after the company posted quarterly results.</li>
</ul>
Commodities In commodity news, oil traded down 0.3% to $68.76 while gold traded up 0.4% at $2,929.50.
Silver traded up 1.4% to $32.28 on Wednesday, while copper rose 1.3% to $4.5875.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.99%, Germany's DAX 40 gained 1.71% and France's CAC 40 climbed 1.15%. Spain's IBEX 35 Index rose 1.64%, while London's FTSE 100 rose 0.72%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.25%, China's Shanghai Composite Index gaining 1.02% and Hong Kong's Hang Seng Index surging 3.27%.
Economics
<ul>
<li>U.S. mortgage applications declined by 1.2% from the previous week during the week ending Feb. 21</li>
<li>U.S. crude oil inventories declined by 2.332 million barrels in the week ended Feb. 21, compared to market estimates of a 2.54 million gain, the EIA said.</li>
<li>Sales of new single-family homes in the U.S. dipped 10.5% to an annualized rate of 657,000 in January.</li>
<li>Building permits declined by 0.6% to an annualized rate of 1.473 million in January.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

VERO

Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings

HC Wainwright &amp; Co. analyst Emily Bodnar downgrades Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) from Buy to Neutral.

Downgrades

HC Wainwright & Co. Downgrades Geron to Neutral

WIIM

Geron Corporation shares are trading lower. The company reported Q4 financial results.

Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 55.56 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $47.54 million which beat the analyst consensus estimate of $45.66 million by 4.11 percent. This is a 206.59K percent increase over sales of $23.00 thousand the same period last year.

Geron Q4 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $47.54M Beat $45.66M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Analysts' ratings for Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Geron, presenting an average target of $6.38, a high estimate of $9.00, and a low estimate of $3.50. Experiencing a 3.63% decline, the current average is now lower than the previous average price target of $6.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1739905264_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Geron by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.50</td>
<td>$5.50</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Geron. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Geron compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Geron's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Geron's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GERN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Geron analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Geron</h2>
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
<h3>A Deep Dive into Geron's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Geron displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 17138.41%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -93.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Geron's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -8.83%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -5.91%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.3, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Geron: What You Need To Know

B. Riley Securities analyst Kalpit Patel maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and lowers the price target from $5.5 to $3.5.

B. Riley Securities Maintains Buy on Geron, Lowers Price Target to $3.5

Needham analyst Gil Blum maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and raises the price target from $6 to $7.

Needham Maintains Buy on Geron, Raises Price Target to $7

Needham analyst Gil Blum reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and maintains $6 price target.

Needham Reiterates Buy on Geron, Maintains $6 Price Target

Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myelodysplastic syndromes (LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission (EC), which has the authority to approve medicines in the European Union (EU), will review the CHMP's recommendation and is expected to make a final decision on the marketing authorization application (MAA) in the following months.

Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes

Press Releases

GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights

Legal

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

Kirby McInerney LLP Urges Investors in Geron Corporation (GERN) to Inquire About Their Rights in Class Action Lawsuit

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit

Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN

GERN Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Geron Corporation (GERN)

Geron Corporation (GERN) Investors: May 12, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

GERN Investors Have the Opportunity to Lead the Geron Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Penny Stocks

Small Cap

GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERN

Comments

Geron

뉴스

에 대한 최신 뉴스 Geron (NASDAQ:GERN) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌